TELL : +91 0 99 08 87 07 06

 Mcmed International ®: Largest Journal Publication in world

Acta Biomedica Scientia

Volume 6, Issue 3, 2019
Mcmed International
Acta Biomedica Scientia
Issn
2348 - 215X (Print), 2348 - 2168 (Online)
Frequency
bi-annual
Email
editorabs@mcmed.us
Journal Home page
http://mcmed.us/journal/abs
Recommend to
A Friend  | A librarian
Purchase
Purchase Issue
Abstract
Title
THALASSEMIA WITH PULMONARY ARTERIAL HYPERTENSION IS AFFECTED BY ACETYLSALICYLIC ACID
Author
Dr. Chenalla Nikhil Laxman
Email
Laxman@gmail.com
keyword
Thalassemia, Cardiography, Patients, Acetylsalicylic Acid
Abstract
The purpose of this study was Comparative study of thalassemic patients with PAH prescribed acetylsalicylic acid (ASA) and pulmonary arterial hypertension (PAH) after one year with those who were not prescribed ASA after one year. The hematological outpatient clinic conducted a retrospective cohort study. First- and 12-month follow-ups were conducted on all new cases of thalassemia with PAH. A two-group classification was used for the patients. A group of patients was prescribed 81 mg of ASA daily for one year, while another group was not prescribed ASA, due to the medication's contraindications, including bleeding and gastrointestinal side effects. The same cardiologist measured PASP using Doppler echocardiography. Indications and contraindications were adjusted using propensity scores. The effects of ASA were evaluated using multivariable regression analysis. The ASA group consisted of 24 (74.6%) thalassemia patients with PAH, while the no ASA group consisted of 8 (25.4%). A comparison between ASA and no ASA showed no significant reduction in The PASP is 0.95, the 95% confidence interval for the difference is 19.99-15.10, and the P value is 0.906. Following one year of treatment with low-dose ASA for PAH in thalassemia, PASP may not improve
Download Broucher
Back to Top >>>>